Longitudinal Evaluation of Hip Cartilage Degeneration: FAI

Launched by HOSPITAL FOR SPECIAL SURGERY, NEW YORK · Mar 31, 2015

Keywords

ClinConnect Summary

This clinical trial is looking at femoroacetabular impingement (FAI), a condition that can cause hip pain and early wear and tear on the hip joint. The study aims to understand which patients might benefit the most from surgery or other treatments by examining their individual characteristics and how their hips are shaped. By doing this, researchers hope to create a better plan for treating people with FAI, helping doctors decide who should have surgery and who might do better with non-surgical options.

To participate in the study, you need to be 35 years old or younger and have a confirmed diagnosis of FAI from an MRI. If you agree to join, you’ll fill out some questionnaires that will help assess your hip condition and how it affects your daily life and activities. It's important to note that if you're over 35 or have already had surgery for hip issues, you won’t be eligible for this trial. Overall, this study is a great opportunity for younger patients with FAI to contribute to research that could improve treatment options for their condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients 35 years of age or younger enrolled in the HSS Hip Preservation Registry prior to September 30, 2016 with an MRI confirmed diagnosis of FAI will be eligible for inclusion in this study regardless of surgery status.
• • Patients who agree to participate must complete a baseline questionnaire consisting of: 1) Modified Harris Hip Score (MHHS), an overall measure of hip condition; 2) the Hip Outcome Score (HOS), a measure developed specifically for younger active patients that measures quality of life and levels of sports and recreation; and 3) International Hip Outcome Tool (iHOT33), a newly developed hip specific outcome score, which measures a number of subscores relating to physical and social functioning with hip problems.
• Exclusion Criteria:
• • Patients over age 35 will be excluded as the focus of this study is early changes that may predispose to later degenerative changes.
• • Patients undergoing revision hip arthroscopy as their first treatment in the Registry will not be eligible, as these are patients who have failed initial therapy.
• • Patients with no complete questionnaires at any time point will be excluded.